PMID- 27413998
OWN - NLM
STAT- MEDLINE
DCOM- 20170928
LR  - 20220331
IS  - 1547-6901 (Electronic)
IS  - 1547-691X (Linking)
VI  - 13
IP  - 5
DP  - 2016 Sep
TI  - Effects of thymol and carvacrol on T-helper cell subset cytokines and their main 
      transcription factors in ovalbumin-immunized mice.
PG  - 729-37
LID - 10.3109/1547691X.2016.1173134 [doi]
AB  - Thymol and carvacrol, two main components of thyme, have several valuable effects 
      on the immune system. This study aims to evaluate the effects of these components 
      on T-helper (TH) cell responses and their subsets in mice immunized with 
      ovalbumin. The effects of these components on: a specific in vivo immune response 
      were evaluated by assessing changes in delayed-type hypersensitivity (DTH); ex 
      vivo splenocyte proliferative responses were evaluated using a BrdU assay gene 
      expression of cytokines and key transcription factors involved in T-cells subset 
      differentiation among the mouse splenocytes were assessed using real-time 
      polymerase chain reaction (PCR); and splenocyte cytokine formation (ex vivo) and 
      levels of the cytokines in mouse sera were measured by ELISA. Mice treated with 
      thymol or carvacrol had reduced DTH responses (26% and 50%, respectively) 
      compared with control mice. Thymol and carvacrol each diminished splenocyte 
      proliferation to nearly 65-72% of control levels (p < 0.01). These agents also 
      led to decreased TH1 [interleukin (IL)-2, interferon (IFN)-gamma)], TH2 (IL-4) and 
      TH17 (IL-17A) levels in the splenocyte cultures and in the sera of mice but 
      increased levels of IL-10 and transforming growth factor (TGF)-beta. Treated 
      immunized mice showed significantly reduced T-box 21 (T-bet) expression from 3.8 
      [+/- 0.3]-fold in untreated ovalbumin-immunized mice to 0.9 [+/- 0.4]-(thymol) and 
      0.8 [+/- 0.2]-fold (carvacrol) (p < 0.01). GATA binding protein 3 (GATA-3) 
      expression declined from 3.4 [+/- 0.4]- to 0.5 [+/- 0.3]-fold (thymol) and 0.6 
      [+/- 0.4]-fold (carvacrol), whereas RORgammac decreased from 13.4 [+/- 1.6]- to 1.5 
      [+/- 0.6]-fold (thymol) and 0.8 [+/- 0.4]-fold (carvacrol) (p < 0.001). As carvacrol 
      and thymol each suppressed the antigen-specific immune response by reducing TH 
      cell-related cytokines\specific transcription factors, this indicated their 
      potential to modulate destructive immune responses attributed to T-cells 
      over-activation.
FAU - Gholijani, Nasser
AU  - Gholijani N
AD  - a Autoimmune Disease Research Center, Shiraz University of Medical Sciences , 
      Shiraz , Iran ;
FAU - Amirghofran, Zahra
AU  - Amirghofran Z
AD  - b Department of Immunology and Medicinal and Natural Products Chemistry Research 
      Center , Shiraz University of Medical Sciences , Shiraz , Iran.
LA  - eng
PT  - Journal Article
DEP - 20160714
PL  - England
TA  - J Immunotoxicol
JT  - Journal of immunotoxicology
JID - 101201960
RN  - 0 (Antigens)
RN  - 0 (Cymenes)
RN  - 0 (Cytokines)
RN  - 0 (GATA3 Transcription Factor)
RN  - 0 (Monoterpenes)
RN  - 0 (Nuclear Receptor Subfamily 1, Group F, Member 3)
RN  - 0 (T-Box Domain Proteins)
RN  - 0 (T-box transcription factor TBX21)
RN  - 3J50XA376E (Thymol)
RN  - 9006-59-1 (Ovalbumin)
RN  - 9B1J4V995Q (carvacrol)
SB  - IM
MH  - Animals
MH  - Antigens/immunology
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Cymenes
MH  - Cytokines/metabolism
MH  - GATA3 Transcription Factor/genetics/metabolism
MH  - Hypersensitivity, Delayed/*drug therapy/immunology
MH  - Immunization
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Monoterpenes/*therapeutic use
MH  - Nuclear Receptor Subfamily 1, Group F, Member 3/genetics/metabolism
MH  - Ovalbumin/immunology
MH  - T-Box Domain Proteins/genetics/metabolism
MH  - T-Lymphocyte Subsets/*drug effects/immunology
MH  - T-Lymphocytes, Helper-Inducer/*drug effects/immunology
MH  - Thymol/*therapeutic use
MH  - Thymus Plant/*immunology
MH  - Transcriptional Activation
OTO - NOTNLM
OT  - Carvacrol
OT  - T-helper cells
OT  - immunization
OT  - immunomodulation
OT  - ovalbumin
OT  - thymol
EDAT- 2016/07/15 06:00
MHDA- 2017/09/29 06:00
CRDT- 2016/07/15 06:00
PHST- 2016/07/15 06:00 [entrez]
PHST- 2016/07/15 06:00 [pubmed]
PHST- 2017/09/29 06:00 [medline]
AID - 10.3109/1547691X.2016.1173134 [doi]
PST - ppublish
SO  - J Immunotoxicol. 2016 Sep;13(5):729-37. doi: 10.3109/1547691X.2016.1173134. Epub 
      2016 Jul 14.